Ransomware victim disclosure
← All victimsAbelZeta Pharma
listed as AbelZeta · Claimed by Spacebears · listed 2 months ago
Status timeline
- Listed
Mar 12, 2026
- Data leaked
At a glance
- Group
- Spacebears
- Status
- Data leaked
- Country
- BA
- Sector
- Not Found
- Listed on leak site
- Mar 12, 2026
About the victim
AI dossier — public-source company profileAbelZeta Pharma is a global cell therapy company focused on discovering, developing, and manufacturing T cell-based therapeutics, including CAR-T therapies, to address unmet medical needs in hematologic malignancies, inflammatory and immunological diseases, and solid tumors. The company operates globally and is headquartered in the United States (area code +1 240, suggesting Maryland/DC area). It is an independent biopharmaceutical firm, distinct from Johnson & Johnson despite the group's misleading post framing.
- Industry
- Biotechnology & Cell Therapy (Oncology & Immunology)
Attack summary
Severity: high — Data has been published (data_published status) by the threat actor against a biopharmaceutical company with proprietary CAR-T and cell therapy research; exfiltration of clinical, research, or patient-adjacent data from a pharma/biotech firm constitutes significant sensitive business and potentially regulated data exposure. The misleading J&J framing in the post does not reduce the risk to AbelZeta's actual data.The Spacebears ransomware group claims to have compromised AbelZeta Pharma and has published data (disclosed status: data_published), though the leak post text describes Johnson & Johnson Innovative Medicine rather than AbelZeta, suggesting possible mislabeling or deliberate obfuscation. The nature of exfiltrated data and encryption status are not explicitly described in the post excerpt.
Data the group says was taken
AI dossier — extracted from the leak post- Pharmaceutical research data (inferred from company profile)
- Clinical pipeline information (inferred)
- Internal corporate documents (inferred)
- Employee records (inferred)
- Proprietary cell therapy platform data (inferred)
What the group claims
AbelZeta Pharma is a global cell therapy leader focused on discovering, developing and manufacturing therapeutics to address unmet medical needs across hematologic malignancies, inflammatory and immunological diseases and solid tumors.Partners: AstraZeneca, Janssen (J&J), NovartisInvestors: HSG, Yunfeng Capital, GIC, TF Capital, CICC Capital, Sailing Capital, Dangdai Group, AstraZeneca-CICC Fund170,000+ different files670+ separate archives with experiments on various candidates All studies: CAR032, CAR39, CAR66, CAR168, TIL, CD, Tcell, etc. There are a huge number of files and studies, all of which are confidential and valuable for competitive research. https://www.abelzeta.com/
The leak post
captured from the group's site## Johnson & Johnson Innovative Medicine Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals) is the pharmaceutical division of the American corporation Johnson & Johnson, specializing in the development and production of revolutionary medicines. The company focuses on creating treatments for the most complex diseases, transforming the future of healthcare.
Sources
Source
Indexed 2 months agoThis page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.
